Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Concerns about AI-generated content accuracy and misinformation are raised.

A user started taking 0.25mg of finasteride every other day to prevent hair loss and documented their experience. Initially, they felt anxious and had headaches, but by the second week, they felt normal with no side effects or changes in hair.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.

Batana Oil is discussed for its potential benefits in promoting hair growth and addressing balding and receding hairlines, though scientific evidence is lacking. The user seeks personal experiences and any supporting information on its effectiveness.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

Isoflavones from soybeans may help limit estrogen's effects on the body, potentially preventing gyno. However, surgery is the only way to remove gland enlargement.

Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

A 29-year-old male on 1 mg Finasteride for 3 months has experienced a significant increase in testosterone and estradiol levels, with no major side effects except slightly oilier skin and increased emotional sensitivity. The user is concerned about these hormonal changes and seeks advice, as their general practitioner is not knowledgeable about the issue.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Breezula results are awaited, but no updates have been posted. Users are uncertain about its promise.

A user asks about experiences with Minichek F 5% with Procapil, specifically its drying time. Responses discuss the effectiveness and drying time of the treatment.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

Verteporfin is discussed as a potential treatment for hair regrowth, but skepticism exists about its effectiveness in regenerating extracted hair follicles. The conversation also mentions the possibility of needing a hair transplant by 2028.

A user had a bad experience with MV Supplements when their Pyril powder and ethanol order leaked during shipping, making the products unusable. Despite contacting support and providing evidence, the company's return policy did not allow for a refund or replacement.

The user shared their positive experience with a 1,500 graft FUE hair transplant at NewHair Institute in Korea, highlighting the natural design by Dr. Jino Kim and the supportive staff. They experienced minimal discomfort and swelling, and appreciated the thorough aftercare and communication.

A user is seeking a reliable exosome hair treatment in NYC, expressing concerns about clinic credibility and wait times. Another user shares their experience, noting that exosomes are investigational, suggesting bloodwork before treatment, and emphasizing that exosomes should complement, not replace, minoxidil.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

Increased coffee intake might be linked to hair shedding, but the cause is unclear. The user is on finasteride and has increased water intake, possibly affecting electrolyte balance.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The conversation discusses using stemoxydine as a carrier for RU58841 and the search for affordable, premixed PG+E. Minoxidil is considered as an alternative, but simplicity is preferred.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.